Morgan Stanley Maintains Overweight on Acelyrin, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Overweight rating on Acelyrin (NASDAQ:SLRN) and raises the price target from $29 to $39.
September 05, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Acelyrin and raises the price target from $29 to $39, which could lead to a positive market reaction.
The raised price target by Morgan Stanley indicates a positive outlook for Acelyrin. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100